Edition:
United Kingdom

Emergent BioSolutions Inc (EBS.N)

EBS.N on New York Stock Exchange

60.96USD
14 Dec 2018
Change (% chg)

$-1.19 (-1.91%)
Prev Close
$62.15
Open
$61.48
Day's High
$62.31
Day's Low
$60.51
Volume
103,847
Avg. Vol
128,729
52-wk High
$73.83
52-wk Low
$42.71

Chart for

About

Emergent BioSolutions Inc. is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical... (more)

Overall

Beta: 1.27
Market Cap(Mil.): $1,669.07
Shares Outstanding(Mil.): 41.21
Dividend: --
Yield (%): --

Financials

  EBS.N Industry Sector
P/E (TTM): 29.50 31.13 34.39
EPS (TTM): 1.37 -- --
ROI: 7.33 15.55 14.96
ROE: 10.48 16.92 16.52

Emergent-Valneva Zika vaccine clears early trial

A vaccine to prevent infections caused by the deadly mosquito-borne Zika virus induced immune response and was found to be safe in an early stage trial, Emergent BioSolutions Inc and partner Valneva SE said on Monday.

19 Nov 2018

Emergent-Valneva Zika vaccine clears early trial

Nov 19 A vaccine to prevent infections caused by the deadly mosquito-borne Zika virus induced immune response and was found to be safe in an early stage trial, Emergent BioSolutions Inc and partner Valneva SE said on Monday.

19 Nov 2018

Emergent BioSolutions to buy Narcan maker Adapt Pharma

Emergent BioSolutions Inc said on Tuesday it would buy privately held Adapt Pharma, beefing up its portfolio with Narcan, the only FDA approved needle-free emergency opioid overdose treatment.

28 Aug 2018

UPDATE 2-Emergent BioSolutions to buy Narcan maker Adapt Pharma

* Adapt partner Opiant soars in after-hours trading (Adds details and comment from conference call)

28 Aug 2018

Emergent BioSolutions to buy Adapt Pharma for up to $735 mln

Aug 28 Emergent BioSolutions Inc said on Tuesday it would buy privately held Adapt Pharma for up to $735 million to acquire its drug Narcan, the only needle-free emergency treatment approved to treat opioid overdose.

28 Aug 2018

Earnings vs. Estimates